WallStreetZenWallStreetZen

NASDAQ: TSHA
Taysha Gene Therapies Inc Stock

$3.24+0.28 (+9.46%)
Updated May 24, 2024
TSHA Price
$3.24
Fair Value Price
-$0.05
Market Cap
$605.94M
52 Week Low
$0.50
52 Week High
$3.89
P/E
-6.61x
P/B
11.25x
P/S
46.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.16M
Earnings
-$118.01M
Gross Margin
100%
Operating Margin
-807.8%
Profit Margin
-833.6%
Debt to Equity
1.84
Operating Cash Flow
-$73M
Beta
2.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TSHA Overview

Taysha Gene Therapies Incorporated is a gene therapy company developing and commercializing adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system.Offerings include TSHA-120 for the treatment of giant axonal neuropathy, TSHA-102 for the treatment of Rett syndrome, TSHA-121 for the treatment of CLN1 disease, TSHA-118 for the treatment of CLN1 disease, TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha was incorporated in 2019 and is headquartered in Dallas, TX.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TSHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TSHA ($3.24) is overvalued by 6,508.62% relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TSHA ($3.24) is not significantly undervalued (6,508.62%) relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TSHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TSHA due diligence checks available for Premium users.

Be the first to know about important TSHA news, forecast changes, insider trades & much more!

TSHA News

Valuation

TSHA fair value

Fair Value of TSHA stock based on Discounted Cash Flow (DCF)
Price
$3.24
Fair Value
-$0.05
Undervalued by
6,508.62%
TSHA ($3.24) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TSHA ($3.24) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TSHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TSHA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.61x
Industry
15.58x
Market
32.03x

TSHA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
11.25x
Industry
6.08x
TSHA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TSHA's financial health

Profit margin

Revenue
$3.4M
Net Income
-$24.1M
Profit Margin
-705.4%
TSHA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TSHA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$153.0M
Liabilities
$99.2M
Debt to equity
1.84
TSHA's short-term assets ($130.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TSHA's short-term assets ($130.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TSHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.8M
Investing
-$140.0k
Financing
-$22.0k
TSHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TSHA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TSHA$605.94M+9.46%-6.61x11.25x
MLYS$605.71M-0.25%-5.52x1.85x
PHAT$614.62M+1.94%-2.35x-4.14x
ZYME$616.55M+0.11%-4.90x1.41x
EXAI$592.32M-0.85%-3.61x1.43x

Taysha Gene Therapies Stock FAQ

What is Taysha Gene Therapies's quote symbol?

(NASDAQ: TSHA) Taysha Gene Therapies trades on the NASDAQ under the ticker symbol TSHA. Taysha Gene Therapies stock quotes can also be displayed as NASDAQ: TSHA.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.

What is the 52 week high and low for Taysha Gene Therapies (NASDAQ: TSHA)?

(NASDAQ: TSHA) Taysha Gene Therapies's 52-week high was $3.89, and its 52-week low was $0.50. It is currently -16.71% from its 52-week high and 548% from its 52-week low.

How much is Taysha Gene Therapies stock worth today?

(NASDAQ: TSHA) Taysha Gene Therapies currently has 187,018,275 outstanding shares. With Taysha Gene Therapies stock trading at $3.24 per share, the total value of Taysha Gene Therapies stock (market capitalization) is $605.94M.

Taysha Gene Therapies stock was originally listed at a price of $24.06 in Sep 24, 2020. If you had invested in Taysha Gene Therapies stock at $24.06, your return over the last 3 years would have been -86.53%, for an annualized return of -48.74% (not including any dividends or dividend reinvestments).

How much is Taysha Gene Therapies's stock price per share?

(NASDAQ: TSHA) Taysha Gene Therapies stock price per share is $3.24 today (as of May 24, 2024).

What is Taysha Gene Therapies's Market Cap?

(NASDAQ: TSHA) Taysha Gene Therapies's market cap is $605.94M, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Taysha Gene Therapies's market cap is calculated by multiplying TSHA's current stock price of $3.24 by TSHA's total outstanding shares of 187,018,275.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.